Lifevantage Corp (LFVN): EBITDA
$8.87M
Year ended 2026-06-30
+4.2%
3-year compound annual growth
-15.9%
5-year compound annual growth
-5.3%
10-year compound annual growth
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $8.87M | -42.2% | 2026-08-27, From 2025-07-01 |
| 2025-06-30 | $15.36M | +94.0% | 2026-08-27, From 2024-07-01 |
| 2024-06-30 | $7.91M | +1.0% | 2025-09-04, From 2023-07-01 |
| 2023-06-30 | $7.84M | -27.7% | 2024-08-28, From 2022-07-01 |
| 2022-06-30 | $10.84M | -48.6% | 2023-08-28, From 2021-07-01 |
| 2021-06-30 | $21.07M | +15.5% | 2022-08-23, From 2020-07-01 |
| 2020-06-30 | $18.24M | +55.8% | 2022-08-23, From 2019-07-01 |
| 2019-06-30 | $11.71M | +0.5% | 2021-08-19, From 2018-07-01 |
| 2018-06-30 | $11.65M | +91.2% | 2020-08-18, From 2017-07-01 |
| 2017-06-30 | $6.09M | -60.2% | 2019-08-14, From 2016-07-01 |
| 2016-06-30 | $15.31M | -5.4% | 2018-08-15, From 2015-07-01 |
| 2015-06-30 | $16.18M | -25.0% | 2017-09-07, From 2014-07-01 |
| 2014-06-30 | $21.57M | +57.1% | 2016-12-12, From 2013-07-01 |
| 2013-06-30 | $13.73M | -37.5% | 2015-09-01, From 2012-07-01 |
| 2012-06-30 | $21.98M | +461.1% | 2014-09-10, From 2011-07-01 |
| 2011-06-30 | $3.92M | n/a | 2013-09-12, From 2010-07-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Lifevantage Corp (LFVN) | 2026-06-30 | $8.87M | -42.2% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | -$9.09M | n/m |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$191.52M | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$159.35M | n/m |
| Liquidia Corp (LQDA) | 2025-12-31 | -$49.85M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$224.0K | n/m |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | -$156.61M | n/m |
| Macrogenics Inc (MGNX) | 2025-12-31 | -$65.67M | n/m |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $50.18M | +141.0% |
Compare LFVN, CYRX, RYTM, PHAT side by side · Screen every company in Pharmaceutical Preparations ↗